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ALBUMINURIA PREDICTING OUTCOME IN THE GENERAL POPULATION
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An elevated urinary albumin excretion predicts de novo devel-
opment of renal function impairment in the general population.
Background. We questioned which factors determine the risk
for developing renal function impairment. To that purpose,
we studied the incidence of newly diagnosed impaired renal
function (GFR <60 mL/min/1.73m2) in the PREVEND cohort
(N = 8592), which is enriched for the presence of albuminuria,
and which was first studied in 1997–1998. Of this cohort, 6894
subjects were studied again four years later.
Methods. Subjects with known renal disease, GFR <60 mL/
min, missing GFR values, or sediment abnormalities at the first
screening were excluded from the present analysis (N = 872).
We examined whether albuminuria is associated with the de
novo development of an impaired renal function. GFR was 90.3
(SD 16.3) mL/min/1.73m2 at baseline, and 11.6% of the subjects
had an albuminuria of more than 30 mg/day.
Results. After a follow-up of four years, 253 subjects (4.2%)
were found to have a GFR <60 mL/min/1.73m2. The subjects
with newly diagnosed impaired GFR were older, had a higher
blood pressure, serum cholesterol, plasma glucose, and urinary
albumin excretion at the first examination, and had a lower
GFR to start with than those with a GFR >60 at the second
evaluation. Subjects with de novo impaired GFR had a compa-
rable BMI and smoked less frequently compared with subjects
with GFR >60. In multivariate analysis, urinary albumin excre-
tion was independently predictive for the risk of developing an
impaired GFR (P = 0.001).
Conclusion. Also in the general population, measurement
of urinary albumin excretion may prove to be a valuable tool
to detect subjects at risk for later development of renal failure,
independent of the presence of other cardiovascular risk factors.
Urinary albumin excretion (UAE) is a predictor of re-
nal function impairment in diabetic subjects. Patients with
type 1 diabetes frequently have an elevated glomerular
filtration rate (GFR) the first decade after the diagnosis
of the diabetes. In that period, UAE gradually increases
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to the level of microalbuminuria (30–300 mg/24h). In sub-
sequent years, the risk for developing overt nephropathy
and progressive renal failure is particularly high for those
with microalbuminuria [1]. This elevated UAE is not only
a renal risk marker, but also a cardiovascular risk marker
in diabetes [2–4]. In the general population albuminuria
has also been proven to be of predictive value as marker
for increased cardiovascular morbidity and mortality [5–
7]. However, longitudinal data on the predictive value of
albuminuria for renal morbidity and mortality are, thus,
far limited to diabetes. In the present study, we therefore
aimed to study the association of albuminuria at baseline
and the de novo renal function impairment after four
years’ follow-up in apparently healthy subjects.
METHODS
Study design and population
The Prevention of Renal and Vascular End-stage Dis-
ease (PREVEND) study was initiated in 1997 with the
aim to investigate the impact of urinary albumin excretion
on renal and cardiovascular disease in the general popu-
lation [8]. A cohort drawn from the city of Groningen,
The Netherlands (28–75 years of age), with an over-
sampling of subjects with an elevated urinary albumin
concentration, was screened during two visits at the out-
patient clinic. Pregnancy and insulin use were exclusion
criteria. Overall, 8592 subjects were included. After a
mean follow-up of 4.2 years (range 2.8–6.1), the partic-
ipants were invited for identical visits to the outpatient
clinic. Of the overall cohort, 6894 subjects were seen for
the second screening. Subjects with known renal disease
(N = 47), a GFR <60 mL/min/1.73m2 (N = 336), or uri-
nary sediment abnormalities (leukocytes >75/lL or ery-
throcytes >50 erythrocytes/lL, or leukocytes = 75 and
erythrocytes >5/lL) (N = 316) were excluded. In ad-
dition, 173 subjects were excluded because of missing
data, leaving 6022 subjects for the present analysis. Renal
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function was calculated by the Cockcroft-Gault formula
[9] and by the MDRD formula [10]. The Cockcroft-Gault
formula was corrected for body surface area (BSA), the
MDRD formula is, per definition, corrected for standard
body surface area. Urinary albumin excretion is given as
the mean of two 24-hour urine excretions. Impaired renal
function was defined as GFR <60 mL/min/1.73m2 [11].
At the initial visit, serum creatinine was determined
by Kodak Ektachem dry chemistry (Eastman Kodak,
Rochester, NY, USA), and during follow-up by pho-
tometric determination with the Jaffe´ method without
deproteinization (Merck KGaA, Darmstadt, Germany).
To check whether this change in analytic method may
influence results, serum samples were obtained of 200
subjects known to have serum creatinine values evenly
distributed over a range of 45 to 145 lmol/L. In these sam-
ples, creatinine was measured simultaneously with both
methods. Linear regression analysis was performed us-
ing the procedure proposed by Passing and Bablok [12,
13]. It appeared that serum creatinine measured by pho-
tometric determination was higher in general. To correct
for this systematic bias, a correction formula was intro-
duced: Creatinine corrected = 1.027 X − 8.243, where X
is serum creatinine measured by photometric determina-
tion.
Statistical analyses
Comparison of the population characteristics at base-
line for normal versus impaired renal function at follow-
up were tested for continuous variables by Student t test,
for categorical variables by chi-square test, and for UAE,
because of its skewed distribution, by Kruskal-Wallis test.
We used multivariate logistic regression to study the as-
sociation of baseline UAE (corrected for confounders
measured at baseline) and impaired GFR. The response
variable of the logistic regression model was GFR <60
mL/min/1.73m2. The predictor variables included in the
regression model were UAE, gender, age, mean arte-
rial pressure, BMI, plasma glucose, serum cholesterol,
smoking, the use of antihypertensives, lipid-lowering or
antidiabetic medication, and renal function at baseline.
For optimal goodness of fit, UAE and plasma glucose
were transformed by a natural logarithm. A P value of
<0.05 was considered significant. Repeated analyses were
performed after exclusion of subjects with cardiovascu-
lar disease or diabetes at baseline. Analyses were also
performed with GFR as calculated from the MDRD
formula.
RESULTS
Mean age at the baseline investigations was 48 years
(SD 12), and GFR was 90.3 (SD 16.3) mL/min/1.73m2,
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Fig. 1. Percentage of subjects with de novo renal function impairment
for the categories of UAE at baseline.
Table 1. Population characteristics of subjects with normal GFR
(≥60 mL/min/1.73m2) at baseline according to normal or impaired
GFR at second screening
GFR second screening
mL/min/1.73m2
Baseline characteristics ≥60 <60 P value
N 5769 253
Male gender % 51.1 60.5 0.003
Age years 47 (11) 65 (7) <0.001
Mean arterial pressure 91.1 (11.7) 100.9 (13.2) <0.001
mm Hg
Body mass index kg/m2 26.0 (4.1) 26.3 (3.5) 0.324
Cholesterol mmol/L 5.6 (1.1) 6.0 (1.2) <0.001
Glucose mmol/L 4.8 (1.1) 5.4 (1.9) <0.001
Smoking % 37.1 26.5 0.001
UAE mg/24h 8.7 (6.1–14.7) 13.5 (7.1–30.2) <0.001
GFR mL/min/1.73m2 91.3 (15.8) 66.9 (6.5) <0.001
The mean ± standard deviation is given, except for UAE, which is expressed
as median with the 25th and 75th percentiles.
contained 51.5% men. Of the overall cohort, 696 (11.6%)
subjects were newly diagnosed with an elevated UAE. Of
these, 650 had microalbuminuria and 46 had macroalbu-
minuria (UAE >300 mg/24h). After a follow-up of four
years, 253 subjects (4.2%) had developed a GFR <60 mL/
min/1.73m2. Figure 1 shows an increasing prevalence of
subjects with de novo renal impairment over the vari-
ous categories of baseline UAE. Subjects who developed
de novo renal impairment were older, had a lower GFR,
higher blood pressure, plasma glucose, serum cholesterol,
and UAE at the first screening than those who did not de-
velop renal impairment (Table 1). More men had devel-
oped impaired renal function. Subjects with renal func-
tion impairment were less often smokers compared to
subjects with a GFR >60. No difference in BMI was
observed. Univariately, albuminuria was associated with
de novo impaired renal function (Table 2). After gender
and age adjustment the association was still significant. In
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Table 2. Albuminuria as predictor for GFR< 60 mL/min/1.73m2 after four-year follow-up (logistic regression model)
Unadjusted Age and gender adjusted Adjusted for confoundersa
Odds ratio (95% CI) Odds ratio (95% CI) Odds ratio (95% CI)
Ln UAE 1.63 1.46–1.82 1.31 1.15–1.49 1.30 1.11–1.52
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Fig. 2. Adjusted predicted odds ratio of GFR<60 according to UAE
compared to UAE of 2 mg/24h. The dashed lines indicate the 95%
confidence interval. The gray area indicates the microalbuminuric range
(UAE 30–300 mg/24h).
addition, after correction for the cardiovascular risk fac-
tors, albuminuria remained a predictor for renal function
loss. The impact of baseline albuminuria to predict de
novo renal function impairment is also shown in Figure 2,
which illustrates the predicted odds ratio of a GFR <60
according to UAE adjusted for the confounders in the
multivariate model. Exclusion of the subjects with cardio-
vascular disease or diabetic patients did not influence the
data significantly. Using MDRD-estimated GFR instead
of Cockcroft-Gault–estimated GFR hardly changed the
results of the multivariate model.
DISCUSSION
We have shown that urinary albumin excretion is pre-
dictive for the development of de novo renal function
impairment, independent of gender, age, and cardiovas-
cular risk factors also in the general population.
Renal impairment is common in the general pop-
ulation. However, it is usually asymptomatic, and for
that reason often not diagnosed. The Framingham Heart
Study (data collection 1977–1983) showed that 8.9% of
men and 8.0% of women have elevated serum creati-
nine levels [14]. In the NHANES III (1988–1994), the
prevalence of GFR <60 mL/min/1.73m2 was 4.7% (8.3
million subjects) [15], and in the baseline screening of
our albuminuria-enriched cohort, 312 out of the 8592
(N = 3.6%) subjects had a GFR below 60 mL/min/1.73m2.
Early detection of renal impairment and subsequent insti-
tution of renoprotective treatment may lower the burden
of ESRD, and importantly, cardiovascular morbidity and
mortality [16]. In diabetes, the evidence that microalbu-
minuria predicts renal and cardiovascular complications
resulted in diagnostic and therapeutic guidelines for clin-
ical practice. These guidelines advise to screen patients
with diabetes yearly for the presence of albuminuria
[17]. Therapeutic interventions that lower UAE delay the
occurrence of renal complications in diabetes [18]. In hy-
pertensive patients, a comparable link between albumin-
uria and future renal and cardiac damage is highly likely
[19–21], although screening for microalbuminuria in hy-
pertension is not yet a routine in clinical practice. The
present study shows that even in the general population
UAE is predictive for de novo renal function impairment.
This finding might indicate that screening for albuminuria
in the general population could lead to an early detection
of progressive renal function impairment.
A recently published study of the Framingham Heart
Study described predictors of kidney disease, as defined
by sex-specific lowest 5% of MDRD-estimated GFR [22].
The authors conclude that de novo renal impairment is
predicted by baseline renal function, age, and cardiovas-
cular risk factors. Our data add that in the general popu-
lation albuminuria seems to be a strong risk marker for
the development of renal function impairment compared
with the classic cardiovascular risk factors.
Serum creatinine during follow-up was corrected be-
cause a systematic error was detected that was introduced
by a change in the analytic procedure. When this correc-
tion would not have been applied, the number of subjects
developing a GFR <60 mL/min/1.73m2 was 479 (8.0%).
The results obtained, however, would not be essentially
different. Univariately and multivariately, urinary albu-
min excretion would still predict de novo renal function
impairment significantly: odds ratio of Ln UAE for pre-
dicting a GFR<60 mL/min/1.73m2 unadjusted 1.47 (1.34–
1.61), adjusted for age and gender 1.15 (1.02–1.28), and
adjusted for multiple confounders 1.25 (1.09–1.44).
Our study is limited by the fact that the subjects in-
cluded in the analyses are, by definition, subjects that
survived for four years. It is generally accepted that both
an increased UAE and diminished renal function are
risk factors or indicators for (cardiovascular) mortal-
ity. For these reasons, the presented results may be an
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underestimation. A second limitation is that we used a
formula to estimate renal function instead of directly
measuring renal function.
CONCLUSION
Albuminuria is a strong predictor of diminished renal
function de novo. The risk attributed to albuminuria is
furthermore independent from cardiovascular risk fac-
tors. Albuminuria may, therefore, in the general popula-
tion also prove to be a valuable risk marker for future
renal function decline amenable for screening purposes.
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